UCM-1306

Research use only, not for human use.

UCM-1306 is a potent and orally active allosteric modulator (PAM) of the human dopamine D1 receptor. It increases the maximal effect of endogenous dopamine (DA) in both human and mouse D1 receptors.

UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD).

——

Animal Model:Adult C57BL/6J mice with cocaine-induced hyperactivity model Dosage:1 mg/kg; cocaine (20 mg/kg, sc) Administration:Intraperitoneal injection Result:Increased cocaine-induced hyperlocomotion, suggesting an in vivo potentiation of DA action at the D1R.Animal Model:Adult C57BL/6J mice Dosage:1 mg/kg Administration:Intraperitoneal injection Result:Increased memory trace in C57BL/6J mice.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

2258608-78-3

279.33

C14H14FNO2S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (179.00 mM; Ultrasonic )

CS(=N)(=O)c1ccc(cc1)-c1ccccc1OCF

——

(-20℃)

With Ice Pack

≥ 2 years